PD-1/PD-L1 Inhibitors Show Greater-Than-Additive Synergy With Conventional Therapies in Esophageal Squamous Cell Carcinoma
A new narrative review synthesizes clinical trial evidence showing that combining PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy, radiotherapy, and surgery ...
